Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
age1 is a venture capital organization founded by Alex Colville and Laura Deming, launched in September 2023 as a continuation of The Longevity Fund, the first longevity-focused VC fund. Based in the United States, age1 is dedicated to funding companies that are pioneering research in longevity and healthy aging. The firm aims to support exceptional founders who are addressing core challenges in the field of longevity.
Currently, age1 manages a fund size of $35 million and has invested in a total of 23 companies. The organization is well-capitalized to support its portfolio companies through later funding rounds, ensuring they have the necessary resources to navigate the complexities of developing innovative therapies and technologies. The firm’s notable milestones include its establishment as a leader in the longevity investment space, building on the legacy of The Longevity Fund.
age1 primarily invests in early-stage companies, including angel, pre-seed, seed, and series A rounds. The investment range spans from $500,000 to $4 million, depending on the dynamics of the funding round. The firm targets exceptional founders globally who are developing therapeutics, tools, and technologies aimed at addressing aging and age-related diseases. This focus on early-stage investments allows age1 to back contrarian founders who are often at the forefront of innovative biotech solutions.
The firm emphasizes its commitment to funding companies that aim to extend healthy lifespans through longevity research. age1 seeks to support founders who are developing groundbreaking therapeutics and technologies that challenge conventional approaches to aging. Their investment strategy is characterized by a willingness to back unconventional science that has not yet gained mainstream VC interest, positioning age1 as a unique player in the longevity investment landscape.
age1 has built a diverse portfolio of 23 companies, primarily in the longevity sector. Notable companies include:
Additionally, the portfolio includes companies like Loyal, which develops longevity therapeutics for dogs, and Gordian Biotechnology, which specializes in in vivo gene therapy for aging. Other notable investments include Fauna Bio, Spring Discovery, and Arda Therapeutics, all contributing to advancements in aging research and therapeutics.
Alex Colville: Co-Founder and General Partner at age1. He has a PhD and a strong background in the biology of aging, having studied at Stanford. His expertise lies in the scientific aspects of longevity research.
Laura Deming: Co-Founder and Venture Partner. She is recognized as a pioneer in longevity investing and founded The Longevity Fund in 2011, the first longevity-focused VC fund. Her experience and vision drive age1's mission.
Lily Clayton: Head of Operations, responsible for overseeing the operational aspects of the firm and ensuring smooth functioning.
Kat Kajderowicz: Principal at age1, focusing on sourcing and evaluating investment opportunities in the longevity sector.
Satvik Dasariraju: Principal, contributing to the investment strategy and portfolio management.
Carol Magalhaes: NewCo Chief of Staff, supporting the firm's strategic initiatives and operations.
Maggie Li: Special Projects Lead, managing key projects that align with age1's mission.
Soleil Wizman: Venture Fellow, assisting in research and analysis of potential investments.
Lynetta Wang: Venture Intern, providing support across various functions within the firm.
To pitch to age1, founders should visit their website at age1.com and submit their pitch materials through the provided channels. It is important to include a comprehensive overview of the business model, the team, and the specific challenges the startup aims to address in the longevity space. age1 prefers detailed decks that highlight the scientific foundation of the proposed solutions.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are encouraged, as they can facilitate a more favorable review process.
In September 2023, age1 officially launched with an initial fund size of $35 million, marking its entry into the venture capital landscape focused on longevity. The firm aims to advance the mission of The Longevity Fund, which was the first longevity-focused VC fund founded by Laura Deming in 2011.
Since its launch, age1 has begun to build a portfolio of 23 companies, including notable investments in ALXO, DBTX, MTCR, DTIL, and UBX, all of which are developing innovative solutions in the longevity sector. The firm is actively seeking to expand its portfolio by identifying exceptional founders and groundbreaking technologies.
What are age1's investment criteria?
age1 invests in early-stage companies, focusing on angel, pre-seed, seed, and series A rounds. They look for exceptional founders who are developing innovative solutions in the longevity and healthcare sectors.
How can startups apply or pitch to age1?
Startups can pitch to age1 through their website at age1.com. They encourage founders to provide detailed information about their business model, team, and the problem they are solving in the longevity space.
What makes age1 different from other venture capital firms?
age1 is uniquely focused on longevity and healthy aging, investing in contrarian founders and innovative biotech solutions that target aging and age-related diseases. Their commitment to this niche sets them apart in the venture capital landscape.
What is age1's geographic scope?
age1 invests globally, with a particular emphasis on the United States. They seek exceptional founders from around the world who are addressing challenges in longevity.
What is the typical check size for investments?
age1 typically invests between $500,000 and $4 million, depending on the funding round and the specific needs of the portfolio company.
What kind of support does age1 provide to its portfolio companies?
age1 offers significant value-add through strategic guidance, resources, and access to a strong network within the biotech industry. They are committed to supporting their portfolio companies not only with capital but also with operational and strategic support.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.